Nikhil C. Munshi, MD
Adjunct Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Hematology & Medical Oncology

MBBS, Maharaja Sayajirao University
MD, Maharaja Sayajirao University



Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.

A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.

Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.

VA Boston Healthcare System






Title
Integrative Oncogenomics of Multiple Myeloma
(PI)

SPORE in Multiple Myeloma
(PI)

Molecular Manipulation to Enhance Anti-Myeloma Response
(PI)



Yr Title Project-Sub Proj Pubs
2023 Molecular Manipulation to Enhance Anti-Myeloma Response 2I01BX001584-09
2023 Integrative Oncogenomics of Multiple Myeloma 2P01CA155258-11
2023 Core 1: Administrative Core 2P01CA155258-11-8234
2023 Project 4: Targeting genomic instability and evolution in myeloma 2P01CA155258-11-8233
2023 SPORE in Multiple Myeloma 5P50CA100707-20
2023 Targeting AP Nuclease, a Mediator of Genomic Instability in MM 5P50CA100707-20-8567
2023 Tissue Banking Core 5P50CA100707-20-8564
2022 Targeting AP Nuclease, a Mediator of Genomic Instability in MM 5P50CA100707-19-8567
2022 Tissue Banking Core 5P50CA100707-19-8564
2022 SPORE in Multiple Myeloma 5P50CA100707-19
Showing 10 of 95 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Little JS, Tandon M, Hong JS, Nadeem O, Sperling AS, Raje N, Munshi N, Frigault M, Barmettler S, Hammond SP. Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy. Blood Adv. 2023 Sep 26; 7(18):5485-5495. PMID: 37486599
     
  2. Paiva B, Manrique I, Rytlewski J, Campbell T, Kazanecki CC, Martin N, Anderson LD, Berdeja JG, Lonial S, Raje NS, Lin Y, Moreau P, San-Miguel JF, Munshi NC, Kaiser SM. Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel. Blood Cancer Discov. 2023 Sep 01; 4(5):365-373. PMID: 37486974
     
  3. Samur MK, Szalat R, Munshi NC. Single-cell profiling in multiple myeloma: insights, problems, and promises. Blood. 2023 Jul 27; 142(4):313-324.View Related Profiles. PMID: 37196627
     
  4. Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D. Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma. Clin Cancer Res. 2023 Jul 18. PMID: 37463058
     
  5. Dimopoulos MA, Merlini G, Bridoux F, Leung N, Mikhael J, Harrison SJ, Kastritis E, Garderet L, Gozzetti A, van de Donk NWCJ, Weisel KC, Badros AZ, Beksac M, Hillengass J, Mohty M, Ho PJ, Ntanasis-Stathopoulos I, Mateos MV, Richardson P, Blade J, Moreau P, San-Miguel J, Munshi N, Rajkumar SV, Durie BGM, Ludwig H, Terpos E. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol. 2023 Jul; 24(7):e293-e311. PMID: 37414019
     
  6. Yao Y, Ng JF, Park WD, Samur M, Morelli E, Encinas Mayoral J, Chyra Z, Xu Y, Derebail S, Epstein C, Nabet B, Chesi M, Gray NS, Young RA, Kwiatkowski N, Mitsiades C, Anderson KC, Lin CY, Munshi NC, Fulciniti M. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. Blood. 2023 Jun 08; 141(23):2841-2852. PMID: 36877894; PMCID: PMC10315622; DOI: 10.1182/blood.2022018885;
     
  7. Du T, Song Y, Ray A, Wan X, Yao Y, Samur MK, Shen C, Penailillo J, Sewastianik T, Tai YT, Fulciniti M, Munshi NC, Wu H, Carrasco RD, Chauhan D, Anderson KC. Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma. Blood. 2023 May 25; 141(21):2599-2614. PMID: 36630605; PMCID: PMC10273170; DOI: 10.1182/blood.2022017897;
     
  8. Kumar S, Zhao J, Talluri S, Buon L, Mu S, Potluri LB, Liao C, Shi J, Chakraborty C, Gonzalez GB, Tai YT, Patel J, Pal J, Mashimo H, Samur MK, Munshi NC, Shammas MA. Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal Adenocarcinoma. Gastroenterology. 2023 Aug; 165(2):357-373.View Related Profiles. PMID: 37178737
     
  9. Samur MK, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi AH, Szalat R, Shammas MA, Sperling AS, Richardson PG, Magrangeas F, Minvielle S, Perrot A, Corre J, Moreau P, Thakurta A, Parmigiani G, Anderson KC, Avet-Loiseau H, Munshi NC. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood. 2023 Apr 06; 141(14):1724-1736.View Related Profiles. PMID: 36603186; PMCID: PMC10273091; DOI: 10.1182/blood.2022017094;
     
  10. Delforge M, Otero PR, Shah N, Moshkovich O, Braverman J, Dhanda DS, Lanar S, Devlen J, Miera M, Gerould H, Campbell TB, Munshi NC. Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial. Leuk Res. 2023 Jun; 129:107074. PMID: 37087950
     
Showing 10 of 565 results. Show More